Anzeige
Mehr »
Login
Dienstag, 28.06.2022 Börsentäglich über 12.000 News von 664 internationalen Medien
Breaking News! Kickt „Yumy Bear" die Konkurrenz aus den Shops?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PSNF ISIN: US6300873022 Ticker-Symbol: NV3P 
Frankfurt
28.06.22
08:14 Uhr
1,895 Euro
-0,019
-0,99 %
Branche
Nanotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOVIRICIDES INC Chart 1 Jahr
5-Tage-Chart
NANOVIRICIDES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8591,96320:55

Aktuelle News zur NANOVIRICIDES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.05.Pre-market Movers: Nutanix, WalkMe, Snowflake, iSpecimen, NanoViricides1.009BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the GreenNanoViricides, Inc. (NNVC) is up over 11% at $2.22 iQIYI...
► Artikel lesen
20.05.NNVC, BEST and PYR among mid-day movers5
17.05.NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application629SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
NANOVIRICIDES Aktie jetzt für 0€ handeln
16.05.NANOVIRICIDES, INC. - 10-Q, Quaterly Report-
16.05.NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis-
16.05.NanoViricides stock rises on starting drug screening program to fight severe hepatitis in kids1
16.05.NanoViricides, Inc.: NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis599SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
25.04.NanoViricides provides update on potential COVID drug NV-CoV-2-
25.04.NanoViricides, Inc.: NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program929SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
15.02.NanoViricides GAAP EPS of -$0.174
15.02.NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready710SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
14.02.NANOVIRICIDES, INC. - 10-Q, Quaterly Report2
16.11.21NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials969SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
15.11.21NanoViricides, Inc.: NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2719SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
13.10.21NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage865SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021...
► Artikel lesen
11.10.21NanoViricides, Inc.: NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity407SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
05.10.21NanoViricides, Inc.: NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference670SHELTON, Conn., Oct. 5, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel...
► Artikel lesen
27.09.21NanoViricides, Inc. Invites You to Join Us at the Benzinga Healthcare Small Cap Conference for Update on Pan-Coronavirus COVID-19 Drug Development Program788Shelton, Connecticut--(Newsfile Corp. - September 27, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on...
► Artikel lesen
22.09.21NanoViricides, Inc.: Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug616SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel...
► Artikel lesen
22.09.21XFRA NV3P: WIEDERAUFNAHME/RESUMPTION457FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1